Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Altimmune Inc.
Headquarters: Gaithersburg, MD, United States of America
Website: http://www.altimmune.com
Year Founded: 1997
Status: Public
Industry Sector: HealthTechnology
CEO: Vipin K. Garg, PhD
Number Of Employees: 59
Enterprise Value: $381,682,507
PE Ratio: -3.33
Exchange/Ticker 1: NASDAQ:ALT
Exchange/Ticker 2: N/A
Latest Market Cap: $343,481,120
BioCentury | Jun 28, 2024
Management Tracks
Forbion taps Dyne vet Brumm to guide growing U.S. presence
Plus: Edward Dulac to become CFO at Intellia, and updates from Altimmune, Bayer, Compass, Sensorion and Neurona
BioCentury | Mar 7, 2024
Product Development
Novo may have best-in-class oral obesity therapy
Phase I oral amycretin data shows 12% placebo-adjusted weight loss at 12 weeks
BioCentury | Dec 4, 2023
Deals
Move into obesity will require deep spending by Roche
After $2.7B takeout of Carmot, bigger investment for Roche will come with development programs, commercial buildup to compete with Novo Nordisk and Lilly
BioCentury | Dec 2, 2023
Product Development
What a pair of Phase II obesity results could mean for Altimmune, Pfizer
Will Altimmune’s pemvidutide be good enough to attract a partner? And will Pfizer go shopping after latest danuglipron data?
BioCentury | Aug 10, 2023
Product Development
Obesity mechanisms in the clinic: which overlap, and which branch out
Like incretins, most clinical programs modulate glucose homeostasis and appetite, but a few work in new ways that could be more selective for fat loss
BioCentury | Mar 29, 2023
Product Development
Next up in obesity therapeutics
Late-stage pipeline dominated by large pharmas, GLP-1 combinations
BioCentury | Mar 21, 2023
Data Byte
Safety readout dims prospects for AltImmune’s obesity therapy
GI effects suggest dual agonist could have trouble finding foothold in competitive area, even if treatment effect strengthens over time
BioCentury | Jan 13, 2023
Finance
2023 catalysts: a buyside view
BioCentury’s 31st annual Buyside View finds that despite the extended downturn, investors see plenty of milestones to drive excitement this year
BioCentury | Jan 5, 2023
Management Tracks
Sanofi’s Sarchi heads to Replimune
Plus: Albers joins Atlas, new CBO at Altimmune and updates from Nuvig, Zymeworks, Fulcrum, Step, Charm, Kymera and more
BioCentury | Sep 15, 2022
Finance
Sept. 14 Quick Takes: Apollomics going public via SPAC deal
Plus RayzeBio raises $160M in series D for radiopharmaceuticals, and updates from Point, Larimar, Worg and more
Items per page:
1 - 10 of 27